Expertise in
16
conditions

Dr. Matthew J. Wieduwilt

Hematology | Oncology
North Carolina Baptist Hospital
1 Medical Ctr Blvd, 
Winston Salem, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
16
conditions
North Carolina Baptist Hospital
1 Medical Ctr Blvd, 
Winston Salem, NC 

Overview

Matthew Wieduwilt is a Hematologist and an Oncologist practicing medicine in Winston Salem, North Carolina.

Dr. Wieduwilt is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 46 peer reviewed articles and participating in 22 clinical trials. Dr. Wieduwilt is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

North Carolina Baptist Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

North Carolina Baptist Hospital
1 Medical Ctr Blvd, Winston Salem, NC 27103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells
A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2026
Intervention Type: Drug, Biological, Procedure, Other
Study Drugs: Carmustine, Cytarabine, Etoposide, Melphalan, CCR5 shRNA/TRIM5alpha/TAR Decoy-Transduced Lentivirus Vector CD34-Positive Progenitor Cells
Study Phase: Phase 1/Phase 2
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2026
Intervention Type: Drug, Biological
Study Drugs: Decitabine, Ipilimumab
Study Phase: Phase 1
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
A Phase I/II Study of Blinatumomab in Combination With Pembrolizumab (MK-3475) for Adults With Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia With High Bone Marrow Lymphoblast Percentage
A Phase I/II Study of Blinatumomab in Combination With Pembrolizumab (MK-3475) for Adults With Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia With High Bone Marrow Lymphoblast Percentage
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drugs: Blinatumomab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: January 30, 2024
Intervention Type: Biological, Drug
Study Drug: Flotetuzumab
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

46 Total Publications

Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 30, 2025
Similar Doctors
Expertise in
32
conditions
Expertise in
32
conditions
Referral may be required

North Carolina Baptist Hospital

1 Medical Ctr Blvd, 
Winston Salem, NC 
 (0.1 miles away)
336-713-5440
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bayard Powell is an Oncologist practicing medicine in Winston Salem, North Carolina. Dr. Powell is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Leukemia, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration. Dr. Powell is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Atrium Health Wake Forest Baptist

S Hawthorne Rd, 
Winston Salem, NC 
 (1.5 miles away)
336-713-5440
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Glenn Lesser is an Oncologist practicing medicine in Winston Salem, North Carolina. Dr. Lesser is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Astrocytoma, Glioma, and Bone Marrow Aspiration. Dr. Lesser is currently accepting new patients.

Expertise in
44
conditions
Dr. Raghava R. Induru
Hematology | Oncology
Expertise in
44
conditions
Dr. Raghava R. Induru
Hematology | Oncology
Referral may be required
Before you request

Atrium Health Levine Cancer Institute, A Facility Of Carolinas Medical Center

945-B N. 5th St., 
Albemarle, NC 
 (52.0 miles away)
980-323-7790
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Raghava Induru is a Hematologist and an Oncologist practicing medicine in Albemarle, North Carolina. Dr. Induru is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Chronic Lymphocytic Leukemia (CLL), and Small Cell Lung Cancer (SCLC). Dr. Induru is board certified in American Board Of Family Medicine, Hospice And Palliative Medicine, American Board Of Internal Medicine, and American Board Of Internal Medicine, Medical Oncology. Dr. Induru is currently accepting new patients.

Frequently Asked Questions about Dr. Matthew J. Wieduwilt

How do I make an appointment with Dr. Matthew J. Wieduwilt?

You can book an appointment with Dr. Matthew J. Wieduwilt by calling their office at 336-713-5440. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Matthew J. Wieduwilt a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Matthew J. Wieduwilt is classified as an Elite expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Matthew J. Wieduwilt specialize in?

While Dr. Matthew J. Wieduwilt is a Hematology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Leukemia, and Acute Myeloid Leukemia (AML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Matthew J. Wieduwilt participate in research or clinical trials?

Yes. Dr. Matthew J. Wieduwilt has published 46 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Matthew J. Wieduwilt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Matthew J. Wieduwilt accept my insurance?

Dr. Matthew J. Wieduwilt accepts most major insurance plans, including Aetna and AmeriHealth. We recommend calling the office directly at 336-713-5440 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wieduwilt's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile